Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

10816	Companies
234408	Keywords
163265	Articles
125414	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 10/02/2025 at 06:30, 10 months 8 days ago

Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron. Commercial launch expected in Q4/2026

Formycon Regeneron Valorum Biologics Aflibercept Biosimilar Patent Disputes
BRIEF

published on 09/17/2025 at 16:00, 10 months 23 days ago

Formycon AG : Recherche et prévisions de performance actualisées

Prévisions De Revenus Formycon FYB202 Biosimilaires FYB206
BRIEF

published on 09/17/2025 at 16:00, 10 months 23 days ago

Formycon AG: Updated Research and Performance Forecast

Revenue Forecast Biosimilars Formycon FYB202 FYB206
PRESS RELEASE

published on 09/17/2025 at 15:55, 10 months 23 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates rating on Formycon AG (ISIN: DE000A1EWVY8) to Buy with a target price of €48. Analyst expects revenue to rebound in H2 and Q4 due to FYB202 and FYB206 developments

First Berlin Equity Research BUY Rating Formycon AG Update Target Price
BRIEF

published on 09/17/2025 at 06:35, 10 months 23 days ago

Horus Pharma rejoint la commercialisation du biosimilaire Eylea® de Formycon

Commercialisation Formycon Biosimilaire Baiama Horus Pharma
BRIEF

published on 09/17/2025 at 06:35, 10 months 23 days ago

Horus Pharma Joins Formycon's Eylea® Biosimilar Commercialization

Commercialization Biosimilar Formycon Baiama Horus Pharma
PRESS RELEASE

published on 09/17/2025 at 06:30, 10 months 23 days ago

Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
Horus Pharma partners with Formycon for Eylea biosimilar commercialization in Europe under Baiama brand. Agreement includes upfront payments and royalties for Klinge. Aflibercept treats nAMD

Agreement Formycon Eylea Biosimilar Horus Pharma Baiama Brand
BRIEF

published on 08/13/2025 at 06:35, 11 months 28 days ago

Formycon confirme ses perspectives pour l'ensemble de l'année après des développements stratégiques

Formycon AG Obligations D'entreprise Orientations Financières 2025 Marché Des Biosimilaires FYB202 Et FYB206
BRIEF

published on 08/13/2025 at 06:35, 11 months 28 days ago

Formycon Affirms Full-Year Outlook After Strategic Developments

Formycon AG Corporate Bond Biosimilar Market 2025 Financial Guidance FYB202 & FYB206
PRESS RELEASE

published on 08/13/2025 at 06:30, 11 months 28 days ago

Formycon confirms full-year guidance following business development in line with plan – working capital raised
Formycon AG confirms full-year guidance with successful business development. Working capital raised through oversubscribed corporate bond. Strong second half expected

Working Capital Business Development Formycon AG Corporate Bond Full-year Guidance

Accesswire

Published on 08/10/2026 at 21:35, 23 minutes ago

Sekur Private Data Government Team Attending DoDIIS Worldwide Intelligence Conference
Published on 08/10/2026 at 20:30, 1 hour 28 minutes ago

Clean Air Metals and Fiore-backed Springbok Ventures Announce Upsize of Non-Brokered Private Placement
Published on 08/10/2026 at 15:30, 6 hours 28 minutes ago

Silver Spruce Resources, Inc. Announces New Chief Financial Officer
Published on 08/10/2026 at 15:25, 6 hours 33 minutes ago

Gemdale Gold Intersects 5.19m at 14.01 g/t Au within 110m at 1.18 g/t Au at the Pontio Gold Project, Finland
Published on 08/10/2026 at 14:30, 7 hours 28 minutes ago

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

View all ACCESSWIRE

EQS Group

Published on 08/10/2026 at 20:24, 1 hour 34 minutes ago

EQS-Adhoc: PNE AG updates on ongoing sales process
Published on 08/10/2026 at 19:35, 2 hours 23 minutes ago

Kontron AG: All conditions of the mandatory tender offer of Ennoconn Corporation are met – Settlement will take place shortly
Published on 08/10/2026 at 19:00, 2 hours 58 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 03 AOUT 2026 au 07 AOUT 2026
Published on 08/10/2026 at 18:29, 3 hours 29 minutes ago

Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Published on 08/10/2026 at 17:50, 4 hours 8 minutes ago

Disclosure according to Article 5(1)(b) of the EU Regulation No. 596/2014 and Article 2(3) of the Delegated EU Regulation No. 2016/1052 - 1st Interim Report

Les Echos

Published on 08/10/2026 at 18:00, 3 hours 58 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 3 hours 58 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 4 hours 13 minutes ago

Weekly share buyback
Published on 08/10/2026 at 17:45, 4 hours 13 minutes ago

Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 10 hours 5 minutes ago

GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026

View all LES ECHOS COMFI WIRE